Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MNMD Mind Medicine (MindMed)	$8.44 -7.2%	$7.82	$4.70 ▼ $10.44	$686.78M	2.49	1.21 million shs	1.60 million shs
NAGE Niagen Bioscience	$9.04 -3.3%	$11.88	$2.53 ▼ $14.69	$736.50M	2.13	1.10 million shs	1.08 million shs
SXTC China SXT Pharmaceuticals	$1.70 +9.0%	$1.70	$0.95 ▼ $8.72	$181M	1.24	67,715 shs	88,794 shs
UPB Upstream Bio	$15.54 +1.5%	$11.38	$5.14 ▼ $29.46	$823.59M	N/A	426,689 shs	514,108 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MNMD Mind Medicine (MindMed)	-7.15%	-13.52%	+19.21%	+21.79%	-8.86%
NAGE Niagen Bioscience	-3.32%	-3.00%	-28.14%	+13.00%	+194.46%
SXTC China SXT Pharmaceuticals	+8.97%	+6.92%	-4.49%	-25.44%	-80.86%
UPB Upstream Bio	+1.50%	+14.01%	+39.62%	+79.86%	+1,553,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MNMD Mind Medicine (MindMed)	1.9119 of 5 stars	3.6	1.0	2.2	0.8	0.6
NAGE Niagen Bioscience	1.0385 of 5 stars	3.5	0.0	0.6	0.0	0.0
SXTC China SXT Pharmaceuticals	0.4957 of 5 stars	0.0	5.0	0.0	0.0	0.6
UPB Upstream Bio	2.0252 of 5 stars	3.5	0.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.00	184.36% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.22	46.24% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
UPB Upstream Bio	3.00	Buy	$56.50	263.58% Upside

Current Analyst Ratings Breakdown

Latest SXTC, MNMD, NAGE, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
NAGE Niagen Bioscience	$99.60M	7.15	$0.06 per share	158.07	$0.60 per share	15.07
SXTC China SXT Pharmaceuticals	$1.93M	102.20	N/A	N/A	$243.66 per share	0.01
UPB Upstream Bio	$2.30M	364.09	N/A	N/A	$8.77 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.53	N/A	N/A	N/A	N/A	-47.29%	-38.29%	N/A
NAGE Niagen Bioscience	$8.55M	$0.17	53.18	∞	N/A	13.07%	19.06%	12.20%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest SXTC, MNMD, NAGE, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	UPB Upstream Bio	-$0.61	N/A	N/A	N/A	$0.32 million	N/A
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.38	-$0.50	-$0.12	-$0.50	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
NAGE Niagen Bioscience	N/A	3.66	3.12
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
UPB Upstream Bio	N/A	47.43	47.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MNMD Mind Medicine (MindMed)	27.91%
NAGE Niagen Bioscience	15.41%
SXTC China SXT Pharmaceuticals	5.02%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
MNMD Mind Medicine (MindMed)	2.45%
NAGE Niagen Bioscience	9.39%
SXTC China SXT Pharmaceuticals	3.95%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A

SXTC, MNMD, NAGE, and UPB Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?

July 31 at 3:55 PM | marketbeat.com

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

July 28, 2025 | tipranks.com

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

July 28, 2025 | tipranks.com

Upstream Bio Inc. (UPB) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Upstream Bio (NASDAQ:UPB) Trading Up 10% - Still a Buy?

July 25, 2025 | marketbeat.com

Upstream Bio begins phase 2 COPD trial for verekitug

July 10, 2025 | uk.investing.com

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...

July 8, 2025 | bakersfield.comB

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

July 8, 2025 | quiverquant.comQ

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

July 8, 2025 | globenewswire.com

UPB Upstream Bio, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.comQ

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

June 15, 2025 | globenewswire.com

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

June 5, 2025 | quiverquant.comQ

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

June 5, 2025 | globenewswire.com

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Upstream Bio names new chief technology officer

May 21, 2025 | investing.com

Upstream Bio Appoints Stacy Price As CTO

May 21, 2025 | nasdaq.com

Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations

May 21, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now
These 2 Tech Stocks With 50%+ ROIC Are Built to Beat the Market
By Leo Miller | July 24, 2025
View These 2 Tech Stocks With 50%+ ROIC Are Built to Beat the Market
Full Steam Ahead: The Bullish Case for Carnival Stock
By Jeffrey Neal Johnson | July 18, 2025
View Full Steam Ahead: The Bullish Case for Carnival Stock
Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?
By Jordan Chussler | July 21, 2025
View Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?

SXTC, MNMD, NAGE, and UPB Company Descriptions

Mind Medicine (MindMed) NASDAQ:MNMD

$8.44 -0.65 (-7.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.62 +0.18 (+2.07%)

As of 08/1/2025 07:55 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Niagen Bioscience NASDAQ:NAGE

$9.04 -0.31 (-3.32%)

As of 08/1/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.70 +0.14 (+8.97%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 08/1/2025 07:48 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Upstream Bio NASDAQ:UPB

$15.54 +0.23 (+1.50%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$15.54 0.00 (-0.03%)

As of 08/1/2025 04:10 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time